Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.

Reiff SD, Mantel R, Smith LL, Greene JT, Muhowski EM, Fabian CA, Goettl VM, Tran M, Harrington BK, Rogers KA, Awan FT, Maddocks K, Andritsos L, Lehman AM, Sampath D, Lapalombella R, Eathiraj S, Abbadessa G, Schwartz B, Johnson AJ, Byrd JC, Woyach JA.

Cancer Discov. 2018 Oct;8(10):1300-1315. doi: 10.1158/2159-8290.CD-17-1409. Epub 2018 Aug 9.

PMID:
30093506
2.

Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.

Reiff SD, Muhowski EM, Guinn D, Lehman A, Fabian CA, Cheney C, Mantel R, Smith L, Johnson AJ, Young WB, Johnson AR, Liu L, Byrd JC, Woyach JA.

Blood. 2018 Sep 6;132(10):1039-1049. doi: 10.1182/blood-2017-10-809020. Epub 2018 Jul 17.

PMID:
30018078
3.

Probing the metabotropic glutamate receptor 5 (mGlu₅) positive allosteric modulator (PAM) binding pocket: discovery of point mutations that engender a "molecular switch" in PAM pharmacology.

Gregory KJ, Nguyen ED, Reiff SD, Squire EF, Stauffer SR, Lindsley CW, Meiler J, Conn PJ.

Mol Pharmacol. 2013 May;83(5):991-1006. doi: 10.1124/mol.112.083949. Epub 2013 Feb 26.

4.

Financial planning: a necessity for the '90s.

Reiff SD, Nelson M.

Comput Healthc. 1993 May;14(5):20-2, 24-5.

PMID:
10125575
5.

Evaluating strategic change using the microcomputer.

Reiff SD.

Healthc Financ Manage. 1987 Jun;41(6):56-7, 60-4.

PMID:
10301590

Supplemental Content

Loading ...
Support Center